Intratumoral and parametrial infusion of a 3-nitrotriazole (AK-2123) in the radiotherapy of the uterine cervix cancer: stage II-III--preliminary positive results.

Abstract

Based on a clinical differential effect of the action of a new hypoxic cell radiosensitizer, AK-2123 (a 3-nitro-1,2,4-triazole), on locally advanced cervix cancer (Stage II-B and III-B), a Phase I/II clinical trial has been carried out on 80 consecutive patients. They were intratumorally injected with AK-2123, wt 1% and 2%, 30 min before the delivery of external radiation therapy. The short-term effects show that exophytic types of lesions respond far better than endophytic types and AK-2123 may be replacing intracavitary radium for exophytic Stage II-B cervix cancer as the standard therapy for this neoplasm in our patients. Treatment is well tolerated and no neurological toxicity has been noted.

• Authors: A H García-Angulo, V T Kagiya
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 22 Issue 3 Pg. 589-91 ( 1992) ISSN: 0360-3016 [Print] United States
• PMID: 1735697 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Radiation-Sensitizing Agents
• Triazoles
• AK 2123

Topics

• Carcinoma, Squamous Cell (drug therapy, radiotherapy)
• Combined Modality Therapy
• Drug Evaluation
• Female
• Humans
• Radiation-Sensitizing Agents (administration & dosage, therapeutic use)
• Triazoles (administration & dosage, therapeutic use)
• Uterine Cervical Neoplasms (drug therapy, radiotherapy)